Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma.
Nordenmark LH, Hellqvist Å, Emson C, Diver S, Porsbjerg C, Griffiths JM, Newell JD, Peterson S, Pawlikowska B, Parnes JR, Megally A, Colice G, Brightling CE. Nordenmark LH, et al. Among authors: brightling ce. NEJM Evid. 2023 Oct;2(10):EVIDoa2300135. doi: 10.1056/EVIDoa2300135. Epub 2023 Sep 20. NEJM Evid. 2023. PMID: 38320181 Clinical Trial.
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium). McDowell PJ, et al. Among authors: brightling ce. Lancet Respir Med. 2021 Oct;9(10):1174-1184. doi: 10.1016/S2213-2600(21)00004-7. Epub 2021 May 7. Lancet Respir Med. 2021. PMID: 33971168
Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
Corren J, Menzies-Gow A, Bimmel J, McGuinness A, Almqvist G, Bowen K, Griffiths JM, Ponnarambil S, Bourdin A, Israel E, Colice G, Brightling CE, Wechsler ME; PATHWAY and NAVIGATOR study investigators. Corren J, et al. Among authors: brightling ce. Immunotherapy. 2023 Nov;15(16):1327-1340. doi: 10.2217/imt-2023-0109. Epub 2023 Sep 29. Immunotherapy. 2023. PMID: 37772607 Free article.
Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study.
Tyrer F, Gharibzadeh S, Gillies C, Lawson C, Routen A, Islam N, Razieh C, Zaccardi F, Yates T, Davies MJ, Brightling CE, Chalmers JD, Docherty AB, Elneima O, Evans RA, Greening NJ, Harris VC, Harrison EM, Ho LP, Horsley A, Houchen-Wolloff L, Leavy OC, Lone NI, Marks M, McAuley HJC, Poinasamy K, Quint JK, Raman B, Richardson M, Saunders R, Sereno M, Shikotra A, Singapuri A, Wain LV, Khunti K; PHOSP‐COVID Study Collaborative Group. Tyrer F, et al. Among authors: brightling ce. Diabetes Obes Metab. 2025 Feb;27(2):767-776. doi: 10.1111/dom.16071. Epub 2024 Nov 20. Diabetes Obes Metab. 2025. PMID: 39563623 Free PMC article.
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
Taquet M, Skorniewska Z, Zetterberg H, Geddes JR, Mummery CJ, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Mansoori P, Greening NJ, Harrison EM, Docherty AB, Lone NI, Quint J, Greenhalf W, Wain LV, Brightling CE, Evans RE, Harrison PJ, Koychev I; PHOSP-COVID Study Collaborative Group. Taquet M, et al. Among authors: brightling ce. Brain Commun. 2023 Dec 27;6(1):fcad357. doi: 10.1093/braincomms/fcad357. eCollection 2024. Brain Commun. 2023. PMID: 38229877 Free PMC article.
Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study.
Elneima O, McAuley HJC, Leavy OC, Chalmers JD, Horsley A, Ho LP, Marks M, Poinasamy K, Raman B, Shikotra A, Singapuri A, Sereno M, Harris VC, Houchen-Wolloff L, Saunders RM, Greening NJ, Richardson M, Quint JK, Briggs A, Docherty AB, Kerr S, Harrison EM, Lone NI, Thorpe M, Heaney LG, Lewis KE, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Bakerly ND, Easom N, Echevarria C, Fuld J, Hart N, Hurst JR, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Thompson AR, Jolley C, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WD, McCann GP, Neubauer S, Openshaw PJ, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Smith N, Sheikh A, Brightling CE, Wain LV, Evans RA; PHOSP-COVID Collaborative Group. Elneima O, et al. Among authors: brightling ce. Int J Epidemiol. 2024 Feb 1;53(1):dyad165. doi: 10.1093/ije/dyad165. Int J Epidemiol. 2024. PMID: 39429158 Free PMC article. No abstract available.
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Gharibzadeh S, Routen A, Razieh C, Zaccardi F, Lawson C, Gillies C, Heller S, Davies M, Atkins H, Bain SC, Lone NL, Poinasamy K, Peto T, Robertson E, Young B, Johnston D, Quint J, Valabhji J, Ismail K, Marks M, Horsley A, Docherty A, Harrison E, Chalmers J, Ho LP, Raman B, Brightling C, Elneima O, Evans R, Greening N, Harris VC, Houchen-Wolloff L, Sereno M, Shikotra A, Singapuri A, Wain L, Langenberg C, Dennis J, Petrie J, Sattar N, Leavy O, Richardson M, Saunders RM, McArdle A, McASuley H, Yates T, Khunti K; PHOSP-COVID Study Collaborative Group. Gharibzadeh S, et al. EClinicalMedicine. 2024 Dec 27;79:103005. doi: 10.1016/j.eclinm.2024.103005. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39834716 Free PMC article.
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS; COURSE study investigators. Singh D, et al. Among authors: brightling ce. Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6. Lancet Respir Med. 2025. PMID: 39653044 Clinical Trial.
Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges.
van Boven JFM, Costello RW, Roes KCB, Brusselle GG, Hansen K, Krishnan JA, Brightling CE, Roche N, Siddiqui S, Kirenga BJ, Pinnock H, Chan AHY. van Boven JFM, et al. Among authors: brightling ce. Lancet Respir Med. 2024 Dec 5:S2213-2600(24)00327-8. doi: 10.1016/S2213-2600(24)00327-8. Online ahead of print. Lancet Respir Med. 2024. PMID: 39647486 Review.
417 results